NAD+
The central cellular energy coenzyme whose age-related decline made it the most commercially successful longevity compound of the last decade — though most of the rigorous evidence sits with its oral precursors.
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every cell, essential to energy metabolism, DNA repair via PARP enzymes, and sirtuin-mediated gene regulation. It is not a peptide but a dinucleotide cofactor, grouped with peptides because it shares the same longevity and mitochondrial research space. Intracellular NAD+ declines roughly 50% between young adulthood and old age, and restoring it via intravenous infusion, subcutaneous injection, or oral precursors (NMN, NR) is one of the most-studied interventions in aging research. The underlying biology is well established; clear healthspan or lifespan extension in humans has not yet been demonstrated.
Class
Pyridine dinucleotide coenzyme (not a peptide)
Half-life
Varies by form: IV NAD+ dose-dependent with rapid cellular turnover; NMN ~1–2 h plasma; NR ~8 h plasma; endogenous cycling minutes to hours by tissue
Routes
Intravenous, Subcutaneous, Intramuscular, Oral (precursors NMN/NR)
Category
Immune & Mitochondrial
Researched benefits
What it's studied for
Restores age-associated NAD+ decline
Intracellular NAD+ falls roughly 50% between ages 40 and 70 across most tissues studied. Supplementation with NAD+ or its precursors reliably raises circulating and tissue NAD+ — oral NR at 1,000 mg/day increased peripheral blood NAD+ by up to 142% (Elhassan 2019).
Supports mitochondrial energy production
NAD+ is the primary electron acceptor in glycolysis, the TCA cycle, and fatty acid oxidation, cycling between NAD+ and NADH to drive ATP synthesis. Every cell requires it minute-to-minute, making it central to the mitochondrial-energy rationale behind fatigue and vitality research.
Activates sirtuin longevity pathways
The seven mammalian sirtuins (SIRT1–7) require NAD+ as a substrate for their deacetylase activity — SIRT1 mediates the caloric-restriction response, SIRT3 regulates mitochondrial function, and SIRT6 governs DNA repair. Declining NAD+ with age reduces sirtuin activity, the mechanistic basis of the 'NAD+ decline drives aging' hypothesis.
Enables PARP-mediated DNA repair
Poly(ADP-ribose) polymerases, especially PARP1, consume NAD+ to tag DNA damage sites and recruit repair machinery. Restoring NAD+ availability supports both PARP repair and sirtuin signaling, which compete for the same substrate pool.
Improves metabolic and insulin markers
In a randomized trial, 10 weeks of NMN raised skeletal muscle insulin sensitivity in prediabetic postmenopausal women (Yoshino 2021). NR and NMN trials have also reported modest reductions in inflammatory cytokines (IL-6, TNF-alpha) and improved aerobic performance, though effect sizes are typically modest.
Neurological and recovery research
A Parkinson's trial demonstrated brain NAD+ elevation with NR (Brakedal 2022), and community reports frequently describe improved energy, reduced fatigue, and support during long-COVID recovery — although these remain early, anecdotal, and often confounded by stacking.
Mechanism
How it works
NAD+ serves as the cell's primary redox cofactor, accepting electrons in catabolic reactions and cycling between its oxidized (NAD+) and reduced (NADH) forms. This shuttle powers ATP generation through glycolysis, the citric acid cycle, fatty acid oxidation, and oxidative phosphorylation. The total cellular NAD+ pool is actively maintained by de novo synthesis from tryptophan, salvage from nicotinamide and nicotinic acid, and precursor pathways from NR and NMN.
Beyond energy metabolism, NAD+ is a required substrate for two major enzyme families. Sirtuins (SIRT1–7) consume NAD+ for deacetylase and ADP-ribosyltransferase activity that regulates metabolism, mitochondrial biogenesis, and telomere integrity. PARP enzymes, chiefly PARP1, consume NAD+ to add ADP-ribose chains at sites of DNA damage. Because both families draw on the same pool, rising DNA damage and inflammation with age create a 'PARP drain' that competes with sirtuins — the mechanistic core of the NAD+-decline-drives-aging hypothesis.
NAD+ is also consumed by CD38, a glycohydrolase on immune cells whose expression rises with age and chronic inflammation, accelerating NAD+ depletion. This has spurred interest in CD38 inhibitors as NAD+-preserving agents. Precursors reach the NAD+ pool by distinct routes: NR enters cells via NRK kinases, NMN either enters intact through the Slc12a8 transporter or is dephosphorylated to NR extracellularly, and nicotinamide is salvaged by the rate-limiting enzyme NAMPT.
Directly administered NAD+ — whether intravenous or subcutaneous — has poor cellular uptake and is thought to be degraded extracellularly to smaller precursors (nicotinamide, NR, NMN) before tissue reuptake and recycling. This means IV NAD+ likely acts through the same intracellular pathways as oral precursors rather than by injecting the intact coenzyme into cells, and helps explain why the premium IV route has not shown a proportional evidence advantage over cheaper oral supplementation.
Dosing protocols
Dosing & administration
Dosing reflects protocols reported in research and community literature for educational purposes. It is not medical advice or a recommendation. Most peptides here are not approved for human use.
Reconstitution
Injectable NAD+ is supplied as a lyophilized powder in 100 mg, 250 mg, or 500 mg vials and reconstituted with bacteriostatic water for subcutaneous or intramuscular use; IV NAD+ is compounded and diluted into saline by 503A pharmacies for slow infusion. Store lyophilized product cold and refrigerate after reconstitution.
Beginner (subcutaneous)
- Dose
- 50–100 mg (50,000–100,000 mcg) per injection
- Frequency
- 2–3 times per week
- Timing
- Morning or early afternoon to avoid stimulation-related insomnia
- Duration
- Ongoing with periodic reassessment
- Route
- Subcutaneous
Lower doses reduce flushing and injection-site reactions; titrate up only after tolerance is confirmed.
Intermediate (subcutaneous)
- Dose
- 100–250 mg (100,000–250,000 mcg) per injection
- Frequency
- 2–3 times per week
- Timing
- Before 2–3 PM
- Duration
- Ongoing
- Route
- Subcutaneous
Higher subcutaneous doses may warrant methylation support (TMG, folate, methylcobalamin) to offset methyl-donor demand.
Clinical IV infusion
- Dose
- 250–1,000 mg per session (some clinics up to 1,500 mg)
- Frequency
- Weekly to monthly maintenance after an initial loading course
- Timing
- Delivered as a slow ~90-minute drip
- Duration
- Package-based; varies by clinic
- Route
- Intravenous
Chest tightness, flushing, and nausea are common during infusion and are managed by slowing the drip rate. Typical clinic cost is $200–$1,000 per session.
Oral precursor alternative
- Dose
- NR 500–1,000 mg/day or NMN 250–600 mg/day
- Frequency
- Once daily
- Timing
- Morning; late-day dosing is the most common cause of insomnia complaints
- Duration
- 8–12 weeks to plateau of subjective effects
- Route
- Oral
Precursors carry most of the rigorous human evidence. Start at 250–300 mg and escalate after ~4 weeks of tolerance; NMN 900 mg was safe but added no benefit over 600 mg.
- Oral NAD+ itself has poor bioavailability — the intact molecule is too large and polar to absorb well — so oral precursors (NR, NMN) are preferred over oral NAD+ products despite similar-looking labels.
- Blood NAD+ rises within 2–4 weeks at effective doses; subjective effects on energy and cognition typically emerge at 4–6 weeks and metabolic effects (insulin sensitivity, inflammatory markers) require 8–12 weeks of consistent use.
- For doses above ~500 mg/day of precursors, or in anyone with elevated homocysteine or suboptimal B12/folate, adding methyl donors (TMG, folate, methylcobalamin) is prudent to support methylation.
- There is no FDA-approved NAD+ dose for any of these uses; all injectable and infusion protocols reflect clinic practice, not regulatory guidance.
Evidence
Research & clinical studies (8)
Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women
10 weeks of NMN significantly increased skeletal muscle insulin sensitivity and insulin signaling in overweight/obese postmenopausal women with prediabetes versus placebo (n=25).
PMID 33888596Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults
In a randomized crossover trial, chronic NR was well tolerated and effectively elevated NAD+ metabolism, with initial signals of reduced blood pressure and arterial stiffness.
PMID 29599478Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence
Summarizes in vivo evidence that NAD+ declines with age and that restoring it in aged or diseased animal models extends healthspan and improves metabolic function.
PMID 29514064Mitochondrial quality control in human ageing and longevity
Reviews how mitochondrial quality-control pathways — including NAD+-dependent processes — shape human aging and longevity.
PMID 42374094Extracellular Lactate Reprograms Mitochondrial Metabolism and NAD+/NADH Redox Balance in Blood-Brain Barrier Endothelial Cells via an LDHB-MPC-NAD+ Axis
Lactate oxidation activates NAD+ salvage pathways to maintain redox balance while supporting enhanced mitochondrial function in cerebrovascular endothelial cells.
PMID 42217683The efficacy and safety of nicotinamide riboside in aerobic performance in amateur runners (Liao 2021)
NMN at 300–600 mg improved aerobic capacity in amateur runners, supporting a performance-related effect of NAD+ elevation.
The NADPARK study: nicotinamide riboside in Parkinson's disease (Brakedal 2022)
NR elevated brain NAD+ measured by imaging and was associated with mild clinical and metabolic improvements in early Parkinson's disease.
MIB-626 (microcrystalline NMN) in COVID-19 and acute kidney injury
Confirmed safe elevation of blood NAD+ but showed no improvement on acute kidney injury markers — biomarker movement without outcome movement.
Combinations
Stacking & blends
Mitochondrial longevity stack
Broad mitochondrial and metabolic support
MOTS-c is a mitochondrial-derived peptide running a similar longevity thesis; the two are reported as synergistic for energy metabolism and are commonly paired in longevity protocols.
Cellular aging stack
Age-related cellular maintenance
Epithalon targets telomerase and epigenetic aging pathways while NAD+ supports sirtuin and PARP activity — reported as a synergistic longevity combination.
Sirtuin-support stack
Enhanced sirtuin activation
Resveratrol is an activator of SIRT1, which depends on NAD+ as its substrate; supplying substrate plus activator is a widely used synergistic pairing.
Redox/energy adjunct
Electron-transport and redox support
Methylene Blue acts as an alternative electron carrier in the mitochondrial chain and is listed as compatible with NAD+ for energy-metabolism support.
Safety
Side effects & considerations
Commonly reported effects
Contraindications & cautions
- Pregnancy and breastfeeding — no safety data for pharmacologic dosing
- Active malignancy under treatment — theoretical concern that NAD+ supports tumor DNA repair and proliferation; discuss with oncology
- Severe cardiovascular disease or unstable angina (IV route — chest tightness)
- Active psychosis or severe anxiety disorder (IV route)
- Known hypersensitivity to the formulation
- Severe hepatic impairment
IV NAD+ commonly produces chest tightness, flushing, and nausea during infusion that resolve when the drip is slowed. A 2026 retrospective tolerability comparison (Frontiers in Aging) found IV NAD+ produced an inflammatory white-blood-cell increase that IV nicotinamide riboside did not. Long-term safety of sustained direct NAD+ administration is not well characterized; oral precursors have a more favorable profile. Methylation support may be needed at higher doses to avoid side effects.
FAQ
NAD+ — common questions
Is NAD+ a peptide?
No. NAD+ is a small dinucleotide coenzyme made of a nicotinamide group, an adenine group, two ribose sugars, and two phosphates — not a chain of amino acids. It is grouped with peptides in research-chemical catalogs because it shares the same longevity, mitochondrial, and metabolic research interest.
What is the difference between NAD+, NMN, and NR?
NAD+ is the active coenzyme cells use directly. NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are oral precursors the body converts to NAD+. Because oral NAD+ has poor bioavailability, precursors are the practical way to raise cellular NAD+ by mouth — NR has the most human trial evidence, NMN has strong emerging data.
Does oral NAD+ work?
Direct oral NAD+ is inefficient — the molecule is too large and polar to be absorbed intact, so the body breaks it down to smaller precursors before uptake. Oral NR or NMN supplements are more effective at raising cellular NAD+ than oral NAD+ products despite similar labels.
Is IV NAD+ better than oral precursors?
The evidence base for IV NAD+ is substantially smaller than for oral precursors, and IV NAD+ is likely broken down to NR/NMN before reaching cells anyway. Most published benefits come from oral precursor studies. IV infusions cost $200–$1,000 per session versus roughly $30–150/month for oral precursors, a gap not matched by a proportional evidence advantage.
Does NAD+ extend lifespan or healthspan in humans?
Not demonstrated yet. Animal models show impressive healthspan effects, and human trials confirm NAD+ elevation plus modest improvements in insulin sensitivity and muscle function, but clear healthspan or lifespan extension in people has not been shown. Biomarker movement without outcome movement is the recurring pattern.
What are the side effects of NAD+?
IV NAD+ commonly causes chest tightness, flushing, and nausea during infusion, managed by slowing the rate. Subcutaneous injection causes injection-site reactions. Long-term supraphysiological NAD+ carries a theoretical tumor-support concern since NAD+ fuels all cell proliferation.
Do I need methyl donors with NAD+ or its precursors?
Possibly at higher doses. Nicotinamide is cleared using S-adenosylmethionine as a methyl donor, so chronic high doses can draw on methylation substrate. For doses above ~500 mg/day of precursors, or with elevated homocysteine or low B12/folate, adding TMG, folate, and methylcobalamin is prudent.
Is NAD+ FDA approved?
No. NAD+ has no FDA drug approval for any indication. IV and subcutaneous NAD+ are compounded by 503A pharmacies and offered as a medical service without FDA evaluation. Among precursors, NR is a GRAS dietary ingredient while NMN's US supplement status was excluded in 2022 and reinstated in December 2025.
